statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...

Intellia Therapeutics (NASDAQ:NTLA) investors are sitting on a loss of 66% if they invested three years ago

This is a signal that NTLA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Intellia Therapeutics (NTLA, $27.47) Stochastic Oscillator left the oversold zone on March 28, 2024

Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because...

Better Cathie Wood Stock: Moderna vs. Intellia

This price move could indicate a change in the trend, and may be a sell signal for investors...

Intellia Therapeutics (NTLA, $26.91) price exceeded its 50-day Moving Average on March 22, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Intellia Therapeutics (NTLA, $27.78) price moved above its 50-day Moving Average on March 20, 2024

Intellia Therapeutics (NTLA, $27.37) price exceeded its 50-day Moving Average on March 18, 2024

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics (NTLA, $28.31) price moved above its 50-day Moving Average on March 15, 2024

Intellia Therapeutics (NTLA, $27.54) price exceeded its 50-day Moving Average on March 14, 2024

Intellia Therapeutics (NTLA, $28.7) price moved above its 50-day Moving Average on March 13, 2024

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Volume	692,769.00
52-Wk High	$47.48
52-Wk Low	$19.37

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.37	--	--	N/A
Q4'23	-$1.45	-$1.46	-0.82%	MISSED
Q3'23	-$1.50	-$1.38	7.91%	BEAT
Q2'23	-$1.32	-$1.40	-5.99%	MISSED
Q1'23	-$1.40	-$1.17	16.40%	BEAT

NTLA Intellia Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals